electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone973-290-0097
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$990,000.00
Profitability
Miscellaneous
Employees91
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
electroCore (NASDAQ:ECOR) Frequently Asked Questions
What is electroCore's stock symbol?
electroCore trades on the NASDAQ under the ticker symbol "ECOR."
How were electroCore's earnings last quarter?
electroCore, Inc. (NASDAQ:ECOR) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.04. The firm had revenue of $0.62 million for the quarter. View electroCore's Earnings History.
When is electroCore's next earnings date?
What price target have analysts set for ECOR?
5 analysts have issued 1-year price targets for electroCore's shares. Their predictions range from $9.00 to $24.00. On average, they expect electroCore's share price to reach $13.50 in the next year. This suggests a possible upside of 614.3% from the stock's current price. View Analyst Price Targets for electroCore.
What is the consensus analysts' recommendation for electroCore?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for electroCore in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for electroCore.
What are Wall Street analysts saying about electroCore stock?
Here are some recent quotes from research analysts about electroCore stock:
- 1. According to Zacks Investment Research, "Electrocore, LLC operates as a bio-electronic medicine company. It reseraches and develops therapeutic technologies based in neurology and rheumatology. Electrocore, LLC is based in NJ, United States. " (10/9/2019)
- 2. Evercore ISI analysts commented, "We think the TETRAS-ADL endpoint was most interesting (see image at bottom) … and this will be the primary endpoint in future clinical trials." (8/13/2019)
Has electroCore been receiving favorable news coverage?
News stories about ECOR stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. electroCore earned a news impact score of 0.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for electroCore.
Are investors shorting electroCore?
electroCore saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 1,120,000 shares, a decrease of 10.4% from the August 30th total of 1,250,000 shares. Based on an average daily trading volume, of 221,000 shares, the short-interest ratio is currently 5.1 days. Currently, 5.1% of the shares of the stock are sold short. View electroCore's Current Options Chain.
Who are some of electroCore's key competitors?
Some companies that are related to electroCore include BioSig Technologies (BSGM), Rockwell Medical (RMTI), Edap Tms (EDAP), Fonar (FONR), Second Sight Medical Products (EYES), Fc Global Realty (FCRE), Soleno Therapeutics (SLNO), Helius Medical Technologies (HSDT), IRIDEX (IRIX), Precision Optics (PEYE), Reshape Lifesciences (RSLS), Digirad (DRAD), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU) and CHF Solutions (CHFS).
What other stocks do shareholders of electroCore own?
Who are electroCore's key executives?
electroCore's management team includes the folowing people:
- Mr. Francis R. Amato, CEO & Director (Age 55)
- Mr. Joseph P. Errico, Co-Founder, Chief Science & Strategy Officer, Principal Investor & Director (Age 50)
- Mr. Glenn S. Vraniak, Exec. Officer (Age 56)
- Dr. Peter S. Staats, Sr. Exec. Advisor of Medical & Gov. Affairs (Age 55)
- Mr. Steven M. Mendez, Founder & CTO (Age 58)
When did electroCore IPO?
(ECOR) raised $64 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities acted as the underwriters for the IPO and BTIG was co-manager.
Who are electroCore's major shareholders?
electroCore's stock is owned by a number of of retail and institutional investors. Top institutional investors include Valeo Financial Advisors LLC (0.15%). Company insiders that own electroCore stock include Brian M Posner, Carrie Smith Cox, Francis R Amato, Global Health Innovation Merck, Joseph P Errico, Peter S Staats and Thomas J Errico. View Institutional Ownership Trends for electroCore.
Which institutional investors are buying electroCore stock?
ECOR stock was acquired by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC. Company insiders that have bought electroCore stock in the last two years include Brian M Posner, Carrie Smith Cox, Francis R Amato, Global Health Innovation Merck, Peter S Staats and Thomas J Errico. View Insider Buying and Selling for electroCore.
How do I buy shares of electroCore?
Shares of ECOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is electroCore's stock price today?
One share of ECOR stock can currently be purchased for approximately $1.89.
How big of a company is electroCore?
electroCore has a market capitalization of $55.93 million and generates $990,000.00 in revenue each year. The company earns $-55,820,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. electroCore employs 91 workers across the globe.View Additional Information About electroCore.
What is electroCore's official website?
How can I contact electroCore?
electroCore's mailing address is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. The company can be reached via phone at 973-290-0097 or via email at [email protected]
MarketBeat Community Rating for electroCore (NASDAQ ECOR)
MarketBeat's community ratings are surveys of what our community members think about electroCore and other stocks. Vote "Outperform" if you believe ECOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
